What is the current valuation of the Androgen Deprivation Therapy Market?

The market valuation was 11.93 USD Billion in 2024. Read More

What is the projected market size for the Androgen Deprivation Therapy Market by 2035?

The market is projected to reach 23.44 USD Billion by 2035. Read More

What is the expected CAGR for the Androgen Deprivation Therapy Market during the forecast period 2025 - 2035?

The expected CAGR is 6.33% during the forecast period 2025 - 2035. Read More

Which cancer types are the primary focus of Androgen Deprivation Therapy?

The primary focus is on Prostate Cancer, valued at 15.8 USD Billion, and Breast Cancer, valued at 7.64 USD Billion by 2035. Read More

What are the leading drug classes in the Androgen Deprivation Therapy Market?

Leading drug classes include Gonadotropin-Releasing Hormone Analogues, projected at 7.12 USD Billion, and Anti-Androgens, projected at 5.56 USD Billion by 2035. Read More

How does the route of administration impact the Androgen Deprivation Therapy Market?

The Injectable route is expected to dominate, with a projected value of 11.88 USD Billion by 2035. Read More

What are the different durations of therapy available in the Androgen Deprivation Therapy Market?

Therapy durations include Neoadjuvant Therapy, projected at 7.12 USD Billion, and Adjuvant Therapy, projected at 9.45 USD Billion by 2035. Read More

Who are the key players in the Androgen Deprivation Therapy Market?

Key players include Astellas Pharma, Bayer AG, Johnson & Johnson, and Pfizer Inc. Read More

What trends are influencing the growth of the Androgen Deprivation Therapy Market?

Trends include increasing prevalence of prostate and breast cancer, driving demand for effective therapies. Read More

How does the market segmentation affect the Androgen Deprivation Therapy Market dynamics?

Market segmentation by cancer type, drug class, and route of administration allows for targeted strategies and resource allocation. Read More

Androgen Deprivation Therapy Market

ID: MRFR/Pharma/25119-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

Androgen Deprivation Therapy Market Research Report By Cancer Type (Prostate Cancer, Breast Cancer), By Drug Class (Gonadotropin-Releasing Hormone Analogues (GnRHas), Anti-Androgens, Androgen Biosynthesis Inhibitors, Estrogens), By Route of Administration (Oral, Injectable, Transdermal), By Duration of Therapy (Neoadjuvant Therapy, Adjuvant Therapy, Palliative Therapy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Androgen Deprivation Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.33%

2024 Market Size$ 11.93 Billion

2025 Market Size$ 12.69 Billion

2035 Market Size$ 23.44 Billion

Key Players

Astellas Pharma

Bayer AG

Johnson & Johnson

Sanofi

Pfizer Inc.

Novartis AG

Trends

Personalized Treatment Approaches
Integration of Novel Agents
Increased Patient Engagement

Opportunities

Aging Population
Growing Awareness and Education
Rising Incidence of Prostate Cancer

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Cancer Type (USD Billion)
  1. 4.1.1 Prostate Cancer
  2. 4.1.2 Breast Cancer
2. 4.2 Healthcare, BY Drug Class (USD Billion)
  1. 4.2.1 Gonadotropin-Releasing Hormone Analogues
  2. 4.2.2 Anti-Androgens
  3. 4.2.3 Androgen Biosynthesis Inhibitors
  4. 4.2.4 Estrogens
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Transdermal
4. 4.4 Healthcare, BY Duration of Therapy (USD Billion)
  1. 4.4.1 Neoadjuvant Therapy
  2. 4.4.2 Adjuvant Therapy
  3. 4.4.3 Palliative Therapy
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Astellas Pharma (JP)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer AG (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ipsen S.A. (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eisai Co., Ltd. (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY CANCER TYPE
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY DURATION OF THERAPY
7. 6.7 CANADA MARKET ANALYSIS BY CANCER TYPE
8. 6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY DURATION OF THERAPY
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY CANCER TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY DRUG CLASS
14. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
15. 6.15 GERMANY MARKET ANALYSIS BY DURATION OF THERAPY
16. 6.16 UK MARKET ANALYSIS BY CANCER TYPE
17. 6.17 UK MARKET ANALYSIS BY DRUG CLASS
18. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
19. 6.19 UK MARKET ANALYSIS BY DURATION OF THERAPY
20. 6.20 FRANCE MARKET ANALYSIS BY CANCER TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY DRUG CLASS
22. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
23. 6.23 FRANCE MARKET ANALYSIS BY DURATION OF THERAPY
24. 6.24 RUSSIA MARKET ANALYSIS BY CANCER TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY DRUG CLASS
26. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
27. 6.27 RUSSIA MARKET ANALYSIS BY DURATION OF THERAPY
28. 6.28 ITALY MARKET ANALYSIS BY CANCER TYPE
29. 6.29 ITALY MARKET ANALYSIS BY DRUG CLASS
30. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 ITALY MARKET ANALYSIS BY DURATION OF THERAPY
32. 6.32 SPAIN MARKET ANALYSIS BY CANCER TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY DRUG CLASS
34. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
35. 6.35 SPAIN MARKET ANALYSIS BY DURATION OF THERAPY
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DURATION OF THERAPY
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY CANCER TYPE
42. 6.42 CHINA MARKET ANALYSIS BY DRUG CLASS
43. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
44. 6.44 CHINA MARKET ANALYSIS BY DURATION OF THERAPY
45. 6.45 INDIA MARKET ANALYSIS BY CANCER TYPE
46. 6.46 INDIA MARKET ANALYSIS BY DRUG CLASS
47. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
48. 6.48 INDIA MARKET ANALYSIS BY DURATION OF THERAPY
49. 6.49 JAPAN MARKET ANALYSIS BY CANCER TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY DRUG CLASS
51. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 JAPAN MARKET ANALYSIS BY DURATION OF THERAPY
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DURATION OF THERAPY
57. 6.57 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
59. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY DURATION OF THERAPY
61. 6.61 THAILAND MARKET ANALYSIS BY CANCER TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY DRUG CLASS
63. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
64. 6.64 THAILAND MARKET ANALYSIS BY DURATION OF THERAPY
65. 6.65 INDONESIA MARKET ANALYSIS BY CANCER TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY DRUG CLASS
67. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
68. 6.68 INDONESIA MARKET ANALYSIS BY DURATION OF THERAPY
69. 6.69 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
71. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY DURATION OF THERAPY
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY CANCER TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY DRUG CLASS
76. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 BRAZIL MARKET ANALYSIS BY DURATION OF THERAPY
78. 6.78 MEXICO MARKET ANALYSIS BY CANCER TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY DRUG CLASS
80. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
81. 6.81 MEXICO MARKET ANALYSIS BY DURATION OF THERAPY
82. 6.82 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
84. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY DURATION OF THERAPY
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DURATION OF THERAPY
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DURATION OF THERAPY
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DURATION OF THERAPY
99. 6.99 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
101. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY DURATION OF THERAPY
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DURATION OF THERAPY, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DURATION OF THERAPY, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY CANCER TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DURATION OF THERAPY, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Androgen Deprivation Therapy Market Segmentation

Androgen Deprivation Therapy Market By Cancer Type (USD Billion, 2025-2035)

Prostate Cancer
Breast Cancer

Androgen Deprivation Therapy Market By Drug Class (USD Billion, 2025-2035)

Gonadotropin-Releasing Hormone Analogues
Anti-Androgens
Androgen Biosynthesis Inhibitors
Estrogens

Androgen Deprivation Therapy Market By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal

Androgen Deprivation Therapy Market By Duration of Therapy (USD Billion, 2025-2035)

Neoadjuvant Therapy
Adjuvant Therapy
Palliative Therapy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”